COLESTID Drug Patent Profile
✉ Email this page to a colleague
When do Colestid patents expire, and what generic alternatives are available?
Colestid is a drug marketed by Pfizer and is included in two NDAs.
The generic ingredient in COLESTID is colestipol hydrochloride. There are two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the colestipol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Colestid
A generic version of COLESTID was approved as colestipol hydrochloride by IMPAX LABS on May 2nd, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COLESTID?
- What are the global sales for COLESTID?
- What is Average Wholesale Price for COLESTID?
Summary for COLESTID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 19 |
| Clinical Trials: | 1 |
| Patent Applications: | 332 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for COLESTID |
| What excipients (inactive ingredients) are in COLESTID? | COLESTID excipients list |
| DailyMed Link: | COLESTID at DailyMed |
Recent Clinical Trials for COLESTID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Washington | Phase 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
Pharmacology for COLESTID
| Drug Class | Bile Acid Sequestrant |
| Mechanism of Action | Bile-acid Binding Activity |
US Patents and Regulatory Information for COLESTID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | COLESTID | colestipol hydrochloride | GRANULE;ORAL | 017563-003 | Sep 22, 1995 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | COLESTID | colestipol hydrochloride | GRANULE;ORAL | 017563-004 | Sep 22, 1995 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | COLESTID | colestipol hydrochloride | TABLET;ORAL | 020222-001 | Jul 19, 1994 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COLESTID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | COLESTID | colestipol hydrochloride | TABLET;ORAL | 020222-001 | Jul 19, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for COLESTID
See the table below for patents covering COLESTID around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2293392 | ⤷ Sign Up | |
| European Patent Office | 0592594 | COMPRIMES A HAUTE TENEUR EN CHLORHYDRATE DE COLESTIPOL (COLESTIPOL HYDROCHLORIDE HIGH-CONTENT TABLETS) | ⤷ Sign Up |
| Hungary | T69394 | ⤷ Sign Up | |
| Czech Republic | 9302826 | ⤷ Sign Up | |
| Japan | 3313710 | ⤷ Sign Up | |
| Poland | 169045 | ⤷ Sign Up | |
| Czech Republic | 286958 | Tabletování lékových směsí hydrochloridu colestipolu (Pharmaceutical tablet and process for preparing thereof) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
